India to Malaysia: Efavirenz Export Trade Route

The India to Malaysia Efavirenz corridor is one of India's established pharmaceutical export routes, with 83 shipments documented worth a combined $3.5M USD. The route is dominated by MYLAN LABORATORIES LIMITED, which alone accounts for roughly 75% of all export value, reflecting the consolidated nature of India's efavirenz manufacturing sector.

Across 10 active suppliers, the average shipment value stands at $42.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 70% of all shipments, consistent with efavirenz's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 18 days port-to-port. The route has recorded an annual growth rate of 34.6%, placing it at rank #2 among India's top efavirenz export destinations globally.

On the import side, key buyers of Indian efavirenz in Malaysia include PAHANG PHARMACY SDN BHD,, PAHANG PHARMACY SDN BHD, PAHANG PHARMACY SDN BHD, and 12 others. PAHANG PHARMACY SDN BHD, is the single largest importer with 30 shipments valued at $1.2M USD.

India's efavirenz exports to Malaysia are driven primarily by a handful of large-scale manufacturers. MYLAN LABORATORIES LIMITED with 55 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 10 active exporters signals a competitive but concentrated market — buyers in Malaysia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — MYLAN LABORATORIES LIMITED, MYLAN LABORATORIES LIMITED , CIPLA LIMITED — together account for 97% of total trade value on this route. The average shipment value of $42.1K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as (efamat) efavirenz 600 mg tablets (30's)(100,000 packs x 30's = 3000000 nos) and (efamat) efavirenz 600 mg tablets (30's) , suggesting that buyers in Malaysia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, PAHANG PHARMACY SDN BHD, is the largest importer with 30 shipments worth $1.2M USD — representing 34% of all efavirenz imports from India on this route. A total of 15 buyers are active on this corridor.